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TheMAPK signal transduction cascade is dysregulated in amajority
of human tumors. Here we report that a nanoparticle-mediated
targeting of this pathway can optimize cancer chemotherapy. We
engineered nanoparticles from a unique hexadentate-polyD,L-
lactic acid-co-glycolic acid polymer chemically conjugated to
PD98059, a selective MAPK inhibitor. The nanoparticles are taken
up by cancer cells through endocytosis and demonstrate sustained
release of the active agent, resulting in the inhibition of phosphor-
ylation of downstream extracellular signal regulated kinase. We
demonstrate that nanoparticle-mediated targeting of MAPK inhib-
its the proliferation of melanoma and lung carcinoma cells and
induces apoptosis in vitro. Administration of the PD98059-
nanoparticles in melanoma-bearing mice inhibits tumor growth
and enhances the antitumor efficacy of cisplatin chemotherapy.
Our study shows the nanoparticle-mediated delivery of signal
transduction inhibitors can emerge as a unique paradigm in cancer
chemotherapy.
cancer  signal transduction
Cancer is the second leading cause of mortality in the UnitedStates, with an estimated 1,444,180 new cases and 565,650
deaths in 2008 (1). Standard chemotherapy nonspecifically tar-
gets all dividing cells, resulting in dose-limiting toxicities. Con-
sequently, there is an urgent need to develop novel strategies that
are more specifically targeted against the tumor. The MAPK
pathway comprising of RAS, RAF, MEK, and ERK has been
implicated in a majority of human tumors, often through gain of
function mutations in the RAS and RAF families (2, 3). Indeed,
RAS mutations occur in 30% of all cancer, and are particularly
implicated in over 90% of pancreatic cancers (4) and 50% of
colon cancers (5); RAF mutations are prevalent in over 60% of
melanomas (6) and over 35% of ovarian cancers (7). As a result,
the MAPK pathway has evolved as a focus of intense investi-
gation for developing small molecule inhibitors as targeted
therapeutics.
Another emerging strategy for targeted chemotherapy is to
harness nanovectors for preferential delivery of drugs into the
tumor (8). A wide range of nanovectors, including liposomes,
micelles, polymeric nanoparticles, silicon and gold nanoshells,
polymeric dendrimers, and carbon-based nanostructures, have
been used for drug delivery to the tumor (9). It is well established
that nanoparticles preferentially localize at the tumors as a result
of the enhanced permeation and retention effect (10, 11).
Indeed, a nanoliposomal formulation of cisplatin was shown to
attain 10- to 200-fold increased drug concentration in tumors
during a Phase-I clinical trial (12). However, standard liposomal
or protein carrier-based nanoplatforms have limited control over
drug release. In contrast, controlled-release drug delivery sys-
tems have the potential to induce standardized and durable
clinical responses.
Interestingly, while extensive studies have been done on
delivering cytotoxic agents to solid tumors using nanovectors, no
report exists on combining targeted therapeutics with nanopar-
ticle-based tumor targeting. In this study, we chemically conju-
gated a selective pharmacological inhibitor with a biodegradable
polymer and engineered a nanoparticle that perturbs the MAPK
signaling pathway. The nanoparticles enable sustained drug
release, which results in inhibition of phosphorylation of ERK,
a downstream signal in the MAPK signal-transduction cascade.
This translates into inhibition of cancer cell proliferation and
induction of apoptosis. Furthermore, we demonstrate that a
nanoparticle-enabled targeting of the MAPK pathway inhibits
tumor growth in vivo and enhances the anticancer activity of
cisplatin, a first-line drug for the treatment of most cancers. Our
results open up the possibility of harnessing nanovectors for
modulating oncogenic pathways.
Results and Discussion
Synthesis and Characterization of Polylactic Acid Glycolic Acid-
PD98059 Conjugates. Nanoparticles engineered from biodegrad-
able, biocompatible, and Food and Drug Administration-
approved polymers offer the potential for rapid translation to the
clinics. As a result, we adapted polylactic acid glycolic acid
(PLGA) as the starting polymer to engineer the nanoparticles.
We selected PD98059 as the selective inhibitor to block MAPK
signaling (13). To avoid the characteristic burst release associ-
ated with nanoparticles and achieve a controlled release profile,
PD98059 was conjugated to linear PLGA 5050 1, using amide-
coupling reaction to obtain PLGA-PD98059 (1:1) conjugate 2
(Fig. 1A). The loading of PD98059 in this conjugate was deter-
mined to be 3.0 g/mg of polymer. To increase the drug loading,
we modified the native PLGA 1 to generate hexa-carboxylic
PLGA 8 using the scheme outlined in Fig. 1. The hexa-carboxylic
PLGA 8 enabled conjugation of 6molecules of PD98059 9, which
increased the loading to 60 g/mg (see Fig. 1B). The structure
of molecules generated at each step was confirmed using spec-
troscopic and analytical methods [see supporting information
(SI) Materials and Methods]. We used an emulsion-solvent
evaporation method to formulate the nanoparticles from the
conjugate 9 [PLGA-6(PD98059)] (14), which resulted in the
formation of spherical nanoparicles with a median size distri-
bution of 100 nm, as confirmed by transmission electron mi-
croscopy (TEM) and dynamic laser light scatter (DLS) (see
Fig. 1C).
Engineering PEG Functionalized PD98059-Loaded Nanoparticles. Na-
ked nanoparticles are rapidly cleared by the macrophages fol-
lowing opsonization. Surface modification of the nanoparticle
with PEG has been reported to decrease surface interactions
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with opsonins through steric repulsion (15), thereby conferring
long-circulating property to the nanoparticles (16). PEG has
excellent biocompatibility and is already approved by the Food
and Drug Administration for human use (17). To develop the
‘‘stealth’’ nanoparticles (i.e., to mask them from tissue macro-
phages or the reticuloendothelial system), we synthesized a
PLGA-b-PEG block copolymer 10 by amide coupling of the
carboxylic acid of PLGA with the amine group of 2 KDa amine
ethylene glycol using the coupling reagent HBTU with diiso-
propylethyl amine (DIPEA) as base (Fig. 2A). To optimize the
size and surface coverage of the nanoparticles by PEG we used
varying ratios of PLGA-b-PEG: PLGA-6(PD98059). Light scat-
ter and TEM revealed that the PLGA-b-PEG: PLGA-
6(PD98059) in 1:5 ratio gave the most optimal size distribution
for further studies (see Fig. 2A).
To test whether a ratio of 1:5 of PLGA-b-PEG: PLGA-
6(PD98059) confers optimal surface coverage of the nanopar-
ticles by PEG, we developed a method based on the well-
validated streptavidin-biotin binding to visualize the PEG chains
on the surface of the nanoparticles using TEM. Biotinylated
nanoparticles were engineered from a 1:5 mixture of PLGA-b-
PEG-biotin conjugate 11 (Fig. S1) and PLGA. The nanoparticles
were then probed with streptavidin-gold nanoparticles (5 nm),
cross-sectioned, stained with uranyl acetate, and visualized using
TEM. As seen in Fig. S1, the complexation of the gold nano-
particles at the periphery of the cross-section of PLGA-PEG-
nanoparticles clearly demonstrates that the PLGA-nanoparticle
was surface coated with PEG. No such binding was observed
with nanoparticles that were constructed with nonpegylated
PLGA.
In Vitro-Release Kinetics of PD98059 from Nanoparticles. We next
studied the controlled-release kinetics of PD98059 from the
nanoparticles. To mimic the clinical situation, we incubated the
nanoparticles with tumor-cell lysates, and dialyzed the released
PD98059 against PBS buffer (pH  7). We used 3 different
cancer-cell lines for this study, the B16/F10 melanoma cells, the
MDA-MB-231 breast-cancer cells, and Lewis lung carcinoma
(LLC) cells. As shown in Fig. 2B, incubation with lysates of
MDA-MB-231, B16/F10, and LLC cells resulted in a sustained
release of PD98059 from the nanoparticles, with a faster release
evident with the MDA-MB-231 cell lysate as compared with
B16/F10 and LLC cells.
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Fig. 1. Development of PD98059 loaded nanoparticles. (A) Synthetic scheme for different PLGA-(PD98059)x conjugates. (B) Loading of PD98059 in mono (2)-,
tri (7)- and hexa (9)- dentate PLGA expressed as microgram per milligram of polymer. (C) Representative transmission electron microscopy image of nanoparticles
synthesized from hexadentate PLGA-(PD98059)6 conjugate. (Scale bar, 100 nm.)
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Fig. 2. Engineering pegylated nanoparticles. (A) Synthetic scheme for PEG-b-PLGA conjugate for engineering pegylated nanoparticles. Different ratio of
PLGA-PEG: PLGA-[PD98059]6 results in nanoparticles of different size distribution, as measured by DLS (y-axis  intensity; x-axis  size in nm). (B) Graph shows
physicochemical release kinetics of PD98059 when the nanoparticles are incubated with MDA-MB231, LLC, and B16/F10 cell lysates.
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In Vitro Cellular-Cytotoxicity Assay. We evaluated the anticancer
effects of the PD98059-nanoparticle in a series of in vitro
cytotoxicity assays. Western blot of the cell lysates confirmed the
activated state of ERK, which is downstream of MEK signaling
(data not shown), indicating that these were appropriate cells to
study the effects of nanoparticle-mediated MAPK inhibition.
Furthermore, to factor in the temporal-release kinetics of the
nanoparticle, the cells were incubated for 24, 48, and 72 h in the
presence of increasing concentrations of free drug or nanopar-
ticles. The viability of the cells at the end of the incubation period
was quantified using a colorimetric MTS assay. As shown in Fig.
3A, although there was more cytotoxicity at 24 h with the free
drug as compared with the PD98059-nanoparticle treatment,
this distinction was lost by 72 h, thus confirming the temporal-
release control exerted by the nanoparticles. Interestingly, we
observed different susceptibility to the PD98059-nanoparticle
between cancer cell lines. After 72 h of incubation with nano-
particle (equivalent to 50-M PD98059) treatment, the percent-
age of viable MDA-MB-231 cells (92%) was significantly greater
than in the case of LLC (65%) (Fig. S2) or B16/F10 cells (55%),
indicating that MDA-MB-231 is insensitive to the PD98059-
nanoparticle. B16/F10 was found to be most susceptible, con-
sistent with the up-regulated MAPK signaling in melanoma. In
subsequent studies, we focused on the MDA-MB-231 and B16/
F10 cell lines.
We evaluated apoptosis as a mechanism underlying the effect
of treatment on cell viability. MDA-MB-231 and B16/F10 cells
were treated with PD98059-nanoparticle (equivalent to 50-M
free PD98059) for 48 h, and then labeled with Annexin V-FITC,
amarker for apoptosis. As seen in Fig. S3, PD98059-nanoparticle
failed to induce significant apoptosis in MDA-MB-231 cells. In
contrast, in the B16/F10 cell line, the free drug and PD98059-
nanoparticle resulted in a 61-fold and a 360-fold increase in the
number of cells in late apoptosis, respectively. This discrepancy
between PD98059 and PD98059-nanoparticle is accounted for
by the fact that the number of cells that were in the necrotic stage
following free drug treatment was 51-fold higher than the cells
treated with PD98059-nanoparticle, consistent with the sus-
tained release of the active agent from the nanoparticle. We next
evaluated the effect of the treatments on the phosphorylation
status of ERK in MDA-MB-231 and B16/F10 cells. In the case
of MDA-MB-231, the free drug inhibited ERK signaling by
5-fold, while the PD98059-nanoparticle had no significant effect.
In contrast, both the PD98059 and PD98059-nanoparticles com-
pletely abolished the phospho-ERK signal in the B16/F10 cells
(Fig. S4A). The differences in the phosphorylation of ERK may
possibly explain the distinct outcomes in terms of cell viability for
the 2 cell lines.
Internalization of Nanoparticles. To track the uptake and distribu-
tion of the nanoparticles in the cells, we engineered the nano-
particles from PLGA that was labeled with FITC. The temporal
uptake of FITC-nanoparticle into the B16/F10 and MDA-
MB231 cells was monitored over a 24-h period. The endosomal/
lysosomal compartments in live cells were stained with the
LysoTracker (red) probe. Merged images (yellow) following
epifluorescence microscopy revealed that the FITC-nanopar-
ticles were internalized into the lysosomes within 30 min in
B16/F10, as seen by the colocalization of the signals. In contrast,
internalization into MDA-MB-231 cells was slower than in the
case of B16/F10 cells, and colocalization within endosomes/
lysosomes was evident only at 12-h postincubation (Fig. S4B).
In Vivo Efficacy in B16/F10 Melanoma Model. To validate the anti-
tumor efficacy of MAPK inhibition, we randomly sorted B16/
F10 melanoma-bearing mice into 6 treatment groups: (i) vehicle
control, (ii) free PD98059 (5 mg/kg), (iii) PD98059-nanoparticle
(equivalent to 5 mg/kg of PD98059), (iv) cisplatin (1.25 mg/kg),
(v) PD98059 (5 mg/kg)  cisplatin (1.25 mg/kg), and (vi)
PD98059-nanoparticle (equivalent to 5 mg/kg of PD98059) 
cisplatin (1.25 mg/kg). Cisplatin was administered i.p. 1 day after
the PD98059 administration to achieve a sequential biological
effect of MAPK inhibition, followed by induction of chemother-
apy-induced cytotoxicity. The mice injected with the vehicle
formed large tumors by day 14 and were killed. The animals in
the other groups were also killed at the same time point to
evaluate the effect of the treatments on tumor pathology.
As shown in Fig. 4A, the treatments resulted in significant
tumor inhibition as compared to the vehicle-treated group.
Interestingly, the combination of MAPK inhibition and the
cytotoxic agent, cisplatin, exerted an enhanced antitumor out-
come as compared to either drug alone. This is consistent with
earlier reports, where MAPK inhibitors were found to synergize
with cytotoxic agents (18). Indeed, gross pathological analysis of
the tumor sections stained with H&E (Fig. 4C) revealed large
necrotic areas following treatment with the PD98059-
nanoparticles, cisplatin, and a significant increase when the 2
treatments were combined together. Interestingly, while the
distinction between the mean tumor volume in the free PD98059
plus cisplatin and the PD98059-nanoparticle plus cisplatin-
treated groups was statistically not significant, 50% of the
animals in the latter group showed complete tumor ablation, as
compared to none in the former. Although there was a statis-
tically significant decrease in the body weight of animals follow-
ing treatment (Fig. 4B), the total loss was less than 10%, which
is the predicted cut-off value for indicating nonspecific toxicity (19).
To dissect the mechanism of action for the antitumor activity
of the PD98059-nanoparticle and the synergism observed with
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Fig. 3. Effect of PD98059-loaded nanopaticles on cell proliferation. B16/F10
melanoma and MDA-MB-231 breast-cancer cells were incubated with free
PD98059 (PD), PD98059-nanoparticle (PD-NP), or vehicle (control), for 24 or
72 h. MTS assays were used to determine the temporal cytotoxicity of increas-
ing concentrations of free PD98059 and PD98059-nanoparticles (NP). Data are
expressed as percent of vehicle-treated control (considered as 100%), and
represents mean SEM from at least triplicates. *, P 0.05 vs. vehicle control
(ANOVA followed by Dunnet’s post hoc test).
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cisplatin, we immunostained tumor cross-sections for phosphor-
ylated ERK, which is downstream of the PD98059 target, MEK.
As shown in Fig. 4C, treatment with PD98059 inhibited the
intratumoral levels of phosphorylated ERK, as compared with
vehicle-, free PD98059-, or cisplatin-treated groups. We next
evaluated the tumors for apoptosis using TUNEL-staining. As
shown in Fig. 4C, treatment with PD98059-nanoparticle and
cisplatin induced significant levels of apoptosis, as compared
with vehicle- or PD98059-treated tumors. Furthermore, the
apoptosis induced by cisplatin was potentiated by the pretreat-
ment with PD98059-nanoparticle, which could explain the
greater antitumor outcome seen as compared with either drug
alone.
Conclusion
MEK1/2 are dual-specificity kinases that phosphorylate and
activate ERK, the classical MAP kinase (2). These kinases lie
downstream of RAS/RAF, which are the most commonly mu-
tated members of the MAPK pathway. Additionally, MEK/ERK
signaling is also activated downstream of growth-factor tyrosine-
kinase receptors, such as epidermal growth factor receptor and
MET receptor, which are implicated in tumorigenesis (20, 21).
As a result, targeting MEK or ERK offers the possibility of
exerting an antitumor effect, even in the absence of RAS/RAF
mutations. Activated ERK regulates the functions of multiple
molecules that are implicated in the cell cycle, including p21Cip1,
p16Ink4a, and p15Ink4b. Furthermore, it can phosphorylate and
inactivateproapoptoticBad, resulting in activationof theantiapo-
ptotic Bcl-2 (22). The inhibition of cell proliferation and the
induction of apoptosis following treatment with free PD98059 or
PD98059-nanoparticle are consistent with the inhibition of
phosphorylation of ERK, and the resultant blockage of these
downstream proliferative and antiapoptotic signals. Interest-
ingly, while incubation with cell lysates from all of the 3 cell lines
resulted in the release of the active agent from the nanoparticle
at similar rates, only B16/F10 melanoma and LLC cells were
susceptible to the PD98059-nanoparticles, and there was limited
effect on the MDA-MB-231 breast-cancer cells. Our results
suggest that this could arise from the variability in the uptake of
nanoparticles into distinct tumor cells, indicating that intracel-
lular uptake and processing is a critical factor in governing the
susceptibility of a cancer cell to drug-conjugated nanoparticles.
Further optimization of the nanoparticles with internalizing
peptides or antibodies will be required for targeting cancer cells
that exhibit limited internalization of nanoparticles. The display
of biotin on the surface of the PEG-PLGA:PLGA-PD98059 in
our study indicates that the internalizing peptides can be con-
jugated in a similar manner to the PEG chains. For example,
Ruoslahti et al. (23) have demonstrated that an iRGD peptide
cannot only target tumors in vivo but is also internalized, and can
be used for active targeting of nanoparticles to tumors.
Interestingly, while free PD98059 exerted a superior effect in
vitro as compared with the PD98059-nanoparticle at early time
points, we observed a significant improvement in the therapeutic
efficacy in vivo with the latter. Indeed, the group that recieved
cisplatin plus PD98059-nanoparticles exhibited complete tumor
ablation in some of the animals. This is consistent with earlier
findings where a nanoparticle-conjugated drug had greater
activity in vivo, and arises from the preferential delivery of the
nanoparticles to the tumor and the sustained release of the drug
(24). In a previous study, we observed an increased uptake of
fluorescently labeled pegylated nanoparticles in the tumor in
vivo (14). This is further validated by the greater inhibition of
intratumoral ERK signaling and resulting apoptosis when
treated with the PD98059-nanoparticles as compared with the
free drug. Excitingly, this mechanism-based induction of apo-
ptosis translated into a synergistic effect when combined with a
traditional chemotherapeutic agent, cisplatin, which induces
apoptosis by intercalating with the DNA.
Several components of the present study can facilitate future
therapy in humans: (i) optimization of drug loading using the
hexadentate PLGA can allow the achievement of clinically-
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Fig. 4. Combination therapy of PD98059-NP with cisplatin inhibits B16/F10
melanoma in xenograft mouse model. (A) Graph shows tumor volume of
B16/F10 melanoma in different treatment groups, comparing the effects of
PD98059-nanoparticle (PD-NP) cisplatin, PD-NP, free PD98059, cisplatin, and
free PD90859  cisplatin. The control group received saline. Animals were
treated with PD98059 (free or NP-conjugated) at a dose of 5 mg/kg through
the tail vein. Cisplatin (1.25 mg/kg) was administered i.p. 1 day after the
PD98059 dosing. Animals were killed on day 14. Each animal received 3 doses
of the treatments. (B) Mean body weight of animals in different treatments as
a measure of gross toxicity. All results are mean SEM (n 6–8 per treatment
group). *, P  0.05 vs. vehicle (ANOVA followed by Newman Keul’s post hoc
test). (C) Representative images showing histological staining of the cross
section of the excised tumors in different treatments at 20 magnifications.
(Left) H&E staining of representative tumor cross-sections. (Middle) Tumor
cross-section was immunostained for phospho-ERK (green), and counter-
stained with propidium iodide (red). (Right) Tumor sections were TUNEL-
labeled for apoptosis with the use of Texas Red-labeled nucleotide. Images
were captured using a Nikon Eclipse epifluorescence microscope.
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relevant doses; (ii) the increased in vivo efficacy of nanoparticle-
MEK inhibitor as compared to the free drug indicates that
nanoparticles could evolve as a powerful platform for targeting
oncogenic pathways, while avoiding the off-target mechanism-
driven effects of the inhibitors; and (iii) the synergistic effects
observed when PD98059-nanoparticles were combined with
cisplatin indicate that this could evolve as a powerful multi-
pronged strategy for the management of cancer. In summary,
this study describes a nanotechnology-based strategy for target-
ing cancer and when combined with cytotoxics may emerge as a
previously unrecorded paradigm in the management of cancer.
Materials and Methods
Nanoparticle Synthesis and Characterization. Modified hexadentate PLGA was
synthesized as described in the SI Materials and Methods. A 1:5 mixture of
PLGA-PD98059 and PLGA-PEG conjugates were dissolved in acetone metha-
nol. The entire solution was emulsified in 2% aqueous solution of PVA (80%
hydrolyzed, Mw9,000–10,000) by slow injection with constant homogeni-
zation using a tissue homogenizer. This mini-emulsion was added to a 0.2%
aqueous solution of PVA (80% hydrolyzed, Mw 9,000–10,000) with rapid
mixing for 4 h at room temperature to evaporate any residual acetone or
methanol. Nanoparticles were recovered by ultracentrifugation at 80,000g.
Sizing and morphological analysis was performed by dynamic light scattering
(Malvern Nanozetasizer) and TEM. Level of pegylation was determined using
a gold-nanoparticle streptavidin biotin-based assay as described in the SI
Materials andMethods. Release kinetics of active drug release was quantified
using UV-VIS spectroscopy as described in the SI Materials and Methods.
Cell Viability Assay. Cancer cells in 96-well plates were incubated with increas-
ing concentrations of the PD98059 or PD98059-nanoparticle for 24, 48, or 72 h.
The percentage of viable cells was then quantified with MTS (CellTiter 96
AQueous One Solution) assay.
Apoptosis Study. Induction of apoptosis following treatment was quantified
using AnnexinV-Alexa Fluor 488 binding. Cells were stained according to the
manufacturer’s protocol. Cells were counterstained with propidium iodide
and immediately analyzed using a Becton Dickinson FACSCalibur flow
cytometer.
Drug Uptake and Metabolism. MDA-MB-231 and B16/F10 cells were treated
with FITC-conjugated nanoparticles for a time-course ranging from 30 min to
24 h. The endosomes/lysosomes were labeled with LysoTracker Red. Images
were captured using an epifluorescence microscope (Nikon Eclipse).
Immunoblotting of Cell Extracts. Proteins were electrophoretically resolved on
SDS/PAGE gel, transferred onto polyvinylidene difluoride membranes,
blocked for 1 h with 7% nonfat dry milk, and subsequently incubated over-
night at 4 °C with primary antibodies directed against the phosphorylated or
total forms of ERK1//2 and AKT. Proteins were detected with HRP-conjugated
anti-rabbit secondary antibodies and Lumi-LightPLUS Western blotting sub-
strate. The blots were developed using GeneSnap, and optical density of the
protein bands was quantified using GeneTools.
In VivoMurine B16/F10Melanoma TumorModel. Male C57/BL6 mice (20 g) were
injected with 5105 BL6/F10 melanoma cells into the flanks. The drug therapy
was started after the tumors attained a volume of 25 mm3. The animals were
injected through the tail vein with free PD98059 or PD98059-nanoparticles
(equivalent dose of free PD98059, 5 mg/kg). Animals receiving cisplatin were
injected with the cytotoxic (1.25 mg/kg, i.p.) after one day of the PD98059
administration. Tumor volume was measured as a function of the length and
breadth using the equation l  b2. All animal procedures were approved by
Harvard University Institutional Use and Care of Animals Committee.
Tumor Immunohistology. Permeabilized paraformaldehyde-fixed tumor sec-
tions from different treatment groups were probed for phospho-ERK and
TUNEL (apoptosis) as described in the SIMaterials andMethods, using a rabbit
polyclonal primary antibody against phosphoERK (dilution 1:250).
Statistical Analysis: All results were expressed as mean  SEM of at least
triplicate samples. Statistical comparisons were obtained using 1-way analysis
of variance. Probability (P) values less than 0.05 were considered significant.
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